Author:
Li Lei,Li Ranran,Wu Zhixiong,Yang Xianghong,Zhao Mingyan,Liu Jiao,Chen Dechang
Abstract
AbstractSince the 2019 novel coronavirus disease (COVID-19) outbreak originated from Wuhan, Hubei Province, China, at the end of 2019, it has become a clinical threat to the general population worldwide. Among people infected with the novel coronavirus (2019-nCoV), the intensive management of the critically ill patients in intensive care unit (ICU) needs substantial medical resource. In the present article, we have summarized the promising drugs, adjunctive agents, respiratory supportive strategies, as well as circulation management, multiple organ function monitoring and appropriate nutritional strategies for the treatment of COVID-19 in the ICU based on the previous experience of treating other viral infections and influenza. These treatments are referable before the vaccine and specific drugs are available for COVID-19.
Publisher
Springer Science and Business Media LLC
Subject
Critical Care and Intensive Care Medicine
Reference99 articles.
1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33.
2. Organization WH. clinical-management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected-interim guidance. Published January 28, 2020.
3. Qiu H, Tong Z, Ma P, et al. Intensive care during the coronavirus epidemic. Intensive Care Med. 2020. https://doi.org/10.1007/s00134-020-05966-y.
4. Hui DS, Azhar I, Madani TA, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—the latest, novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2019;2020(91):264–6.
5. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–74.
Cited by
102 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献